Tyrosine Kinase
Tyrosine Kinase(酪氨酸激酶)
- Bcr-Abl(73)
- Ack1(3)
- Axl(6)
- ALK(64)
- BMX Kinase(3)
- Broad Spectrum Protein Kinase Inhibitor(10)
- c-FMS(42)
- c-Kit(58)
- c-MET(99)
- c-RET(7)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(278)
- EphB4(1)
- FAK(39)
- FGFR(104)
- FLT3(97)
- HER2(15)
- IGF1R(34)
- Insulin Receptor(46)
- IRAK(32)
- ITK(10)
- Lck(1)
- LRRK2(25)
- PDGFR(113)
- PTKs/RTKs(10)
- Pyk2(8)
- ROR(41)
- Spleen Tyrosine Kinase (Syk)(33)
- Src(108)
- Tie-2 (4)
- Trk(43)
- VEGFR(200)
- Kinase
- Discoidin Domain Receptor(16)
- DYRK(35)
- Ephrin Receptor(13)
- RET(30)
- ROS(14)
- TAM Receptor(33)
- IGFBR(1)
- Others(55)
Tyrosine Kinase 相关产品(1402)
- GC13761AZD8931 (Sapitinib)CAS: 848942-61-0纯度: >99.50%
A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3
- GC14396Ponatinib (AP24534)CAS: 943319-70-8纯度: >99.00%
Ponatinib (AP24534)是一种多靶点酪氨酸激酶抑制剂,可抑制Abl(IC 50 =0.37nM),PDGFRα(IC 50 =1.1nM),VEGFR2(IC 50 =1.5nM),FGFR1(IC 50 =2.2nM)和Src(IC 50 =5.4nM)的活性。
- GC14807Fingolimod (FTY720) HClCAS: 162359-56-0纯度: >99.50% / >99.00%
芬戈莫德(FTY720)是一种免疫抑制剂,通常用于治疗多发性硬化症,也有抗癌作用,可以作为HDACi(组蛋白脱乙酰酶抑制剂)。
- GC14898Tie2 kinase inhibitorCAS: 948557-43-5纯度: >99.00%
Tie2 kinase inhibitor是一种可逆的选择性Tie2抑制剂,IC50为250 nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC13608 | Lapatinib | 231277-92-2 | >99.50% | |
Lapatinib是一种口服的双重EGFR和HER2酪氨酸激酶抑制剂,对HER2阳性乳腺癌具有显著疗效。Lapatinib对纯化的EGFR和HER2的半数抑制浓度(IC₅₀)值分别为10.2nM和9.8nM。 | ||||
| GC13697 | AG-1024 | 65678-07-1 | >98.50% | |
AG-1024是一种可逆的,竞争性和选择性的胰岛素样生长因子-1受体(IGF-1R)抑制剂,IC 50 值为7μM。AG-1024能够抑制胰岛素受体(IR)的磷酸化,IC 50 值为57μM。 | ||||
| GC13761 | AZD8931 (Sapitinib) | 848942-61-0 | >99.50% | |
A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 | ||||
| GC13914 | Flumatinib mesylate | 895519-91-2 | >99.50% | |
A Bcr-Abl inhibitor | ||||
| GC14189 | AZD-3463 | 1356962-20-3 | >99.50% | |
An ALK and IGF-1R inhibitor | ||||
| GC14214 | BMS-777607 | 1025720-94-8 | >99.00% | |
BMS-777607 是一种泛 TAM 抑制剂,对不同类型的癌症显示出抗肿瘤活性。 | ||||
| GC14238 | Brivanib Alaninate (BMS-582664) | 649735-63-7 | >99.00% | |
A prodrug form of brivanib | ||||
| GC14256 | Tivantinib (ARQ 197) | 905854-02-6 | >99.50% | |
An inhibitor of c-Met | ||||
| GC14315 | SU14813 maleate | 849643-15-8 | >99.50% | |
A dual VEGFR and PDGFR family kinase inhibitor | ||||
| GC14332 | NVP-BHG712 | 940310-85-0 | >99.50% | |
A selective EphB4 kinase inhibitor | ||||
| GC14396 | Ponatinib (AP24534) | 943319-70-8 | >99.00% | |
Ponatinib (AP24534)是一种多靶点酪氨酸激酶抑制剂,可抑制Abl(IC 50 =0.37nM),PDGFRα(IC 50 =1.1nM),VEGFR2(IC 50 =1.5nM),FGFR1(IC 50 =2.2nM)和Src(IC 50 =5.4nM)的活性。 | ||||
| GC14407 | PF-431396 | 717906-29-1 | >98.50% | |
A FAK/PYK2 dual inhibitor | ||||
| GC14489 | Y 11 | 1086639-59-9 | >95.00% | |
An inhibitor of FAK1 | ||||
| GC14534 | Regorafenib monohydrate | 1019206-88-2 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14552 | LDK378 | 1032900-25-6 | >99.50% | |
An ALK inhibitor | ||||
| GC14592 | KW 2449 | 1000669-72-6 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14606 | Regorafenib hydrochloride | 835621-07-3 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14660 | SU 5402 | 215543-92-3 | >98.00% | |
SU 5402是一种多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体2(VEGF-R2)和成纤维细胞生长因子受体1(FGF-R1)酪氨酸激酶活性的IC 50 分别为20nM和30nM。 | ||||
| GC14683 | Sunitinib malate | 341031-54-7 | >99.00% | |
A multi-kinase inhibitor | ||||
| GC14729 | (R)-Crizotinib | 877399-52-5 | >99.50% | |
A c-MET and ALK receptor tyrosine kinase inhibitor | ||||
| GC14733 | SU14813 | 627908-92-3 | >98.50% | |
A dual VEGFR and PDGFR family kinase inhibitor | ||||
| GC14807 | Fingolimod (FTY720) HCl | 162359-56-0 | >99.50% / >99.00% | |
芬戈莫德(FTY720)是一种免疫抑制剂,通常用于治疗多发性硬化症,也有抗癌作用,可以作为HDACi(组蛋白脱乙酰酶抑制剂)。 | ||||
| GC14898 | Tie2 kinase inhibitor | 948557-43-5 | >99.00% | |
Tie2 kinase inhibitor是一种可逆的选择性Tie2抑制剂,IC50为250 nM。 | ||||
| GC15022 | Vandetanib (ZD6474) | 443913-73-3 | >99.50% | |
A multi-kinase inhibitor | ||||
